ES2067604T3 - Anticuerpos frente a proteina que se une a tnf i y a sus fragmentos f(ab). - Google Patents

Anticuerpos frente a proteina que se une a tnf i y a sus fragmentos f(ab).

Info

Publication number
ES2067604T3
ES2067604T3 ES90115105T ES90115105T ES2067604T3 ES 2067604 T3 ES2067604 T3 ES 2067604T3 ES 90115105 T ES90115105 T ES 90115105T ES 90115105 T ES90115105 T ES 90115105T ES 2067604 T3 ES2067604 T3 ES 2067604T3
Authority
ES
Spain
Prior art keywords
fragments
antibodies against
against protein
binds tnf
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90115105T
Other languages
English (en)
Inventor
David Wallach
Harmut Engelmann
Dan Aderka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9122989A external-priority patent/IL91229A/en
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2067604T3 publication Critical patent/ES2067604T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN DICHOS ANTICUERPOS QUE PUEDEN UTILIZARSE EN ENSAYOS DE DIAGNOSTICO Y COMO AGENTES FARMACEUTICOS PARA, BIEN INHIBIR, O ELIMINAR LOS EFECTOS DE TNF EN CELULAS.
ES90115105T 1989-08-06 1990-08-06 Anticuerpos frente a proteina que se une a tnf i y a sus fragmentos f(ab). Expired - Lifetime ES2067604T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL9122989A IL91229A (en) 1989-08-06 1989-08-06 Antibodies to tbp-i and pharmaceutical compositions containing them
IL94039A IL94039A (en) 1989-08-06 1990-04-06 Antibodies to tbp - 1 and their use

Publications (1)

Publication Number Publication Date
ES2067604T3 true ES2067604T3 (es) 1995-04-01

Family

ID=26321966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90115105T Expired - Lifetime ES2067604T3 (es) 1989-08-06 1990-08-06 Anticuerpos frente a proteina que se une a tnf i y a sus fragmentos f(ab).

Country Status (7)

Country Link
EP (1) EP0412486B1 (es)
AT (1) ATE114724T1 (es)
DE (1) DE69014474T2 (es)
DK (1) DK0412486T3 (es)
ES (1) ES2067604T3 (es)
GR (1) GR3014970T3 (es)
IL (1) IL94039A (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL107267A (en) * 1993-10-12 2009-07-20 Yeda Res & Dev Ligand to a member of the tnf/ngf receptor family
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0939121B2 (de) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
EP0589982B1 (de) * 1991-06-19 2001-01-17 Boehringer Ingelheim International GmbH Monoklonale antikörper gegen das humane tnf-bindende protein i (tnf-bp i)
DE4120213C2 (de) * 1991-06-19 2000-01-05 Boehringer Ingelheim Int Monoklonale Antikörper gegen das TNF-bindende Protein I (TNF-BP I)
US5582998A (en) * 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
IT1290018B1 (it) * 1997-03-04 1998-10-19 Vander Way Limited Immunoglobuline citotossiche da mammiferi
IL126024A0 (en) * 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL178921A0 (en) * 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2018140121A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies

Also Published As

Publication number Publication date
ATE114724T1 (de) 1994-12-15
IL94039A (en) 2006-09-05
IL94039A0 (en) 1991-01-31
DE69014474D1 (de) 1995-01-12
GR3014970T3 (en) 1995-05-31
DK0412486T3 (da) 1995-02-27
DE69014474T2 (de) 1995-04-20
EP0412486B1 (en) 1994-11-30
EP0412486A1 (en) 1991-02-13

Similar Documents

Publication Publication Date Title
ES2067604T3 (es) Anticuerpos frente a proteina que se une a tnf i y a sus fragmentos f(ab).
NL193015B (nl) Inrichting voor het meten van stofwisselingsgrootheden.
MX9203364A (es) Anticuerpos que tienen reactividad inmunologica especifica con celulas de carcinoma humano y composiciones farmaceuticas que los contienen.
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
DE3166890D1 (en) Reflecting device to be used in the technique of lighting and photography
DE59301057D1 (de) Einrichtung zur Entnahme von Probeexemplaren in einem Falzapparat.
DE58909630D1 (de) Photopolymerisierbares Gemisch und dieses enthaltendes photopolymerisierbares Aufzeichnungsmaterial
DE3575214D1 (de) Adressauswahlsystem in eingabe/ausgabeplatte.
NO162797C (no) Monoklonalt antistofff for anvendelse in vitro.
DE3586173D1 (de) Einrichtung zur tageslichtlenkung.
DE69032489D1 (de) Ligand/antiligandteste für anklebende proteine
BR9507451A (pt) Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
FI891953L (fi) Monoklonaalinen vasta-aine intaktin prokollageenipeptidin (tyyppi III) ja prokollageenin (tyyppi III) selektiiviseksi immunologiseksi määrittämiseksi ruumiinnesteistä
DE69220080D1 (de) Reagenzzusammensetzung in form von benutzer-einheiten für spezifische bindungstests
DK396185D0 (da) Konsistensproevningsbeholder for sejtflydende materialer
FR2639748B1 (fr) Reliure pour album d'echantillons
IT8722483A0 (it) Composizione bituminosa e suo impiego nel settore dell'impermeabilizzazione.
PT90364A (pt) Anticorpos monoclonais para o activador de plaminogenio de tecidos (t-pa) que prolongam a sua semi-vida funcional
FI882019L (fi) Monoklonaalisia vasta-aineita intaktin prokollageenipeptidin (tyyppi III) ja prokollageenin (tyyppi III) selektiivistä, immunologista määritystä varten kehonnesteistä
DE69026812D1 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
DE3870497D1 (de) Arbeits- und verbindungsplatte fuer arbeitsplatten.
BR8405580A (pt) Linhagens de celulas hibridas que produzem anticorpos monoclonicos dirigidos contra o treponema e sua utilizacao no imuno-diagnostico das infeccoes por treponema
BR9105983A (pt) Anticorpos monoclonais que diferenciam entre proteinas de sequencias nativa e modificada
DK346387A (da) Fremgangsmaade til at reducere alkaliindholdet i cementklinker
DE68902909D1 (de) Fehlgewicht-waegesystem fuer materialien in freiem fluss.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 412486

Country of ref document: ES